AChR阳性重症肌无力临床不同人群的亚单位免疫优势:多参数横断面分析
这项多中心横断面研究纳入513例AChR阳性重症肌无力患者,分析亚单位特异性抗AChR IgG滴度与疾病严重程度、年龄、性别、胸腺受累等的关系。抗AChR滴度随疾病严重程度单调升高,女性滴度更高且随年龄下降;男性以α亚单位免疫优势为主,女性以γ亚单位免疫优势为主。γ免疫优势与更高滴度及严重疾病相关,无监督主成分分析揭示两种疾病内型。
要点
- 抗AChR滴度随MG疾病严重程度单调升高(ρ=0.31)。
- 女性抗AChR滴度高于男性,且女性滴度随年龄单调下降。
- γ亚单位免疫优势与更高滴度及严重MG(MGFA IV-V)相关。
核心结论
- 基于性别、年龄、胸腺受累、抗体滴度和AChR亚单位免疫优势,可区分两种MG内型,提示不同病因及性别依赖精准医学的潜力。
研究设计与样本
- 大型多中心横断面研究,前瞻性招募MG患者并获取生物库血清样本。
- 纳入标准要求MG临床表现且抗AChR IgG滴度阳性(≥0.5 nM),经2次独立检测确认。
- 共纳入513例MG患者(50.5%女性),中位年龄64岁(范围14-98.5);232例有扩展临床数据。
主要发现
- 抗AChR滴度随疾病严重程度单调升高(ρ=0.31,95%CI 0.17-0.44,p<0.0001)。
- 女性抗AChR滴度高于男性(中位14.6 nM vs 7.7 nM,Δ的95%CI 2.1-7.3 nM,p<0.0001),女性滴度随年龄单调下降。
- 男性以α免疫优势为主(男性23.2% vs 女性16.6%,Δ的95%CI 0%-7.6%,p=0.031),女性以γ免疫优势为主(女性30% vs 男性24.5%,Δ的95%CI 2%-11%,p=0.0027)。
- γ免疫优势与更高抗AChR滴度相关(ρ=0.25,95%CI 0.16-0.33,p<0.0001),并与严重疾病(MGFA IV-V)相关(44% vs 27%,Δ的95%CI 4%-34%,p=0.0141)。
- 无监督主成分分析揭示两种内型:内型A为女性中重度早发型MG、γ亚单位免疫优势、高抗AChR滴度及频繁胸腺增生;内型B为其余患者,多为晚发型MG、α亚单位免疫优势及低抗AChR滴度。
关键数值与推荐
- 抗AChR IgG阳性定义为滴度≥0.5 nM,需2次独立检测确认。
- 严重疾病定义为MGFA IV-V级。
临床怎么用
- 临床可结合性别、年龄、胸腺受累、抗AChR滴度及亚单位免疫优势对MG患者进行内型分类。
- 女性早发型中重度MG伴γ免疫优势和高滴度者可能代表特定内型,提示性别依赖的精准医学方向。
局限性
- 横断面设计无法推断因果关系或预测纵向病程。
- 仅232例患者有扩展临床数据,部分分析基于该亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Myasthenia gravis (MG) is a chronic antibody-mediated autoimmune neuromuscular disorder causing fluctuating muscle weakness due to autoantibodies that target the acetylcholine receptor (AChR) in the neuromuscular junction (NMJ). Despite extensive research, MG remains unpredictable and heterogeneous, underscoring the need for better insight into disease pathogenesis and clinical course. The objective of this study was to identify clinical and immunologic disease-related parameters that correlate with disease severity. METHODS: This large-scale, multicenter, cross-sectional study included prospectively recruited patients with MG and MG serum samples procured from reputable biobanks. Inclusion criteria required an MG clinical presentation and a positive anti-AChR immunoglobulin G (IgG) titer (≥0.5 nM), confirmed by 2 independent tests. Enrolled patients underwent profiling of subunit-specific anti-AChR IgG titers. Disease severity patterns and their relation to age, sex, disease onset, thymic involvement, anti-AChR titer, and anti-AChR subunit immunodominance were investigated. RESULTS: The study included 513 patients with MG (50.5% female) with a median age of 64 years (range 14-98.5). Extended clinical data were available for 232 patients. Anti-AChR titers increased monotonically with disease severity (ρ = 0.31, 95% CI 0.17-0.44, p < 0.0001) and were higher in female patients (median 14.6 nM vs 7.7 nM, 95% CI for Δ 2.1-7.3 nM, p < 0.0001) in whom higher antibody titers decreased monotonically with age. Male patients' titers were predominantly alpha-immunodominant (male 23.2% vs female 16.6%, 95% CI for Δ 0%-7.6%, p = 0.031), while female patients' titers were gamma-immunodominant (female 30% vs male 24.5%, 95% CI for Δ 2%-11%, p = 0.0027). Gamma immunodominance correlated with higher anti-AChR titer (ρ = 0.25, 95% CI 0.16-0.33, p < 0.0001) and severe (Myasthenia Gravis Foundation of America IV-V) disease (44% vs 27%, 95% CI for Δ 4%-34%, p = 0.0141). Unsupervised principal component analysis disclosed 2 distinct disease endotypes: female patients with moderate to severe early-onset MG, gamma subunit immunodominance, high anti-AChR titers, and frequent thymic hyperplasia (endotype A) and the remaining patients, mostly patients with late-onset MG, alpha subunit immunodominance, and low anti-AChR titers (endotype B). DISCUSSION: Two distinct MG endotypes emerge based on sex, age, thymic involvement, autoantibody titer, and immunoglobulin AChR subunit immunodominance-suggesting different underlying etiologies with potential implications for sex-dependent precision medicine, women's health, and the development of new therapeutic modalities for MG.
引用
- Oved K, Denkberg G, Pinzur L, et al. Subunit-Specific Immunodominance in Clinically Distinct Populations With AChR+ Myasthenia Gravis: A Multiparametric Cross-Sectional Analysis. Neurology. 2025. PMID: 41021867. doi:10.1212/WNL.0000000000214150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。